Afrezza Quarterly Sales Increase, New Therapies on Horizon at MannKind | San Fernando Valley Business Journal
MannKind Corp. touted increased sales for its flagship drug Afrezza during its fourth quarter earnings report on Thursday, while pointing out its new direction toward therapies for lung and endocrine diseases. During the quarter, MannKind pulled in $10.1 million in revenue for Afrezza, its inhalable insulin, a 30 percent increase compared to sales in the same quarter of 2019. The Westlake Village biotech company reported an adjusted net loss of $13.2 million (-6 cents a share). That’s narrower than the net loss of $14.3 million (-7 cents) in the same period a year earlier. Revenue was $18.4...
Source: sfvbj.com